CAS Number: 1194506-26-7
Fruquintinib is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of specific enzymes, known as tyrosine kinases, which are involved in the growth and spread of cancer cells.
In particular, fruquintinib targets vascular endothelial growth factor receptors (VEGFRs), which play a crucial role in the development of blood vessels that support the growth of tumors. By inhibiting the activity of VEGFRs, fruquintinib slows down the growth of new blood vessels and restricts the blood supply to the tumor, ultimately reducing its size and slowing its progression.
Fruquintinib has been approved in China for the treatment of certain types of advanced or metastatic colorectal cancer, and it is being studied in clinical trials for its efficacy and safety in treating other types of cancer, such as non-small cell lung cancer, gastric cancer, and breast cancer.
Fruquintinib is indicated for the treatment of advanced or metastatic colorectal cancer in China. The drug is intended for patients who have received previous treatment with other chemotherapy drugs and have not responded or have stopped responding to those treatments.
It is important to note that fruquintinib is still being studied in clinical trials for its efficacy and safety in treating other types of cancer, such as non-small cell lung cancer, gastric cancer, and breast cancer. The approval status and indications for fruquintinib may vary depending on the country and the regulatory agencies involved.
Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Fruquintinib API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Fruquintinib API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.
Please fill in the following form for API Requirement & we'll get back to you shortly
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.